potential indications for glp-1 receptor agonists keep expanding Drugs: Where We Are and Where We're Going — Summit Re Extending Healthspan via GLP-1 Receptor

2018;35:e2815

Amgen & Viking Therapeutics 8% Given that our portfolio is built for the next 5 years, it makes sense to allocate a small portion to possible new entrants

This increases the oxidative burden in the body because of the excessive amounts of oxidized glutathione waiting to be recharged by antioxidants

Clinical trials have documented substantial weight loss with these medicationstypically 15% of body weight with semaglutide 2.4 mg (STEP 1 trial) and approximately 21% with tirzepatide 15 mg (SURMOUNT-1 trial) at 72 weeks

READ A D, BENTLEY R E T, MARTIN A Y, et al

Control of gdhR Expression in Neisseria gonorrhoeae via Autoregulation and a Master Repressor (MtrR) of a Drug Efflux Pump Operon